Biotechnology

Cortland Biomedical Secures FDA Registration, Expanding Role as a Trusted Contract Manufacturer for Medical Device OEMs

January 22, 2025 12:15 PM

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing capabilities, is proud to announce its FDA registration, marking a significant milestone in the company's evolution. This new designation positions Cortland Biomedical as a full-service contract manufacturer and reinforces the company's unwavering commitment to delivering the...

Read more

VALID Therapeutics Partners With Araceli Biosciences to Advance AI-Driven Drug Discovery

January 22, 2025 11:00 AM

VALID, a Techbio startup dedicated to reshaping drug discovery with complex human induced pluripotent stem cell (iPSC) co-culture models that deliver increased predictive validity, has partnered with Araceli Biosciences to leverage the cutting-edge Araceli Endeavor® Ultra High Throughput - High Content Imaging Platform. This collaboration enhances VALID's ability to generate high-quality, actionable data at unprecedented speed and scale,...

Read more

Alligator Bioscience AB Reports Full Year Financial Results for 2024 and for Q4 2024 and Provides a Business Update

January 22, 2025 2:20 AM

Alligator Bioscience (STO:ATORX) Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of approximately SEK 280 million, and raised bridge loans; subsequently approved following the quarter at EGM on 13 January 2025 Sale of future financial commitments for two bispecific antibodies to Orion Corporation Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) "We...

Read more

Repair Biotechnologies Announces Positive Pre-IND Meeting With FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia

January 21, 2025 9:00 AM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, is pleased to announce that it has received positive feedback from a Pre-IND meeting with the U.S. Food and Drug Administration (FDA), an important step forward towards opening an IND to conduct a Phase 1b study of its REP-0003 mRNA therapy in patients with...

Read more

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

January 21, 2025 8:30 AM

POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in...

Read more

Tanvex BioPharma Completes Acquisition of Bora Biologics, Launching New Era in Biologics Development

January 19, 2025 6:00 PM

Tanvex BioPharma, Inc. ("Tanvex"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion of its acquisition of Bora Biologics Co., Ltd. ("Bora Biologics"), a subsidiary of Bora Pharmaceuticals. Following this acquisition, Tanvex's CDMO services will operate under the name Bora Biologics, continuing to be owned by Tanvex. "The completion of...

Read more

Univec, Inc. Welcomes Michael Knight to Board of Directors

January 17, 2025 1:15 PM

Univec, Inc. (otcmarket:UNVC) A mental health and substance abuse total wraparound service provider announced that Michael Knight has joined the Board of Directors replacing Chris Farnworth. "We welcome Michael to the board adding his expertise in the mental health sector." said Lamont Ellis President of Univec, Inc. About Univec, Inc. Univec, Inc. is a total wraparound service provider in the mental health and substance abuse sector. Univec...

Read more

Alligator Bioscience Announces Final Terms of Rights Issue

January 17, 2025 12:45 PM

Alligator Bioscience (STO:ATORX) On 2 December 2024, the board of directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") resolved on an issue of units, consisting of ordinary shares and warrants, with preferential rights for the Company's existing shareholders (the "Rights Issue"). The extraordinary general meeting on 13 January 2025 approved the Rights Issue and today, the board of directors of Alligator Bioscience...

Read more

FluoGuide A/S Receives Approval for Phase II Trial in Head and Neck Cancer

January 15, 2025 10:45 AM

KØBENHAVN, DK / ACCESSWIRE / January 15, 2025 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces approval of its phase II Clinical Trial Application for FG001 in head and neck cancer (oral squamous cell carcinoma cancer). The Phase II Clinical Trial Application (CTA) for FG001 in head and neck cancer, announced on October 7, 2024,...

Read more

Bionoid Pharma, Inc. Provides Corporate Update and Outlines Growth Strategy for 2025

January 14, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to provide a corporate update as it looks ahead to a promising year in 2025. The company remains committed to its strategic growth plan, which centers on acquiring revenue-positive e-commerce websites and integrating advanced AI technology to drive expansion in the health and wellness sector. Bionoid's proprietary AI Maverick Intel platform will play a pivotal role in the company's...

Read more

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

January 13, 2025 8:30 AM

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's...

Read more

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

January 13, 2025 6:20 AM

LUND, SE / ACCESSWIRE / January 13, 2025 / Alligator Bioscience (STO:ATORX) Today, on 13 January 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on amendment of the Articles of Association The meeting resolved to amend §§ 4-5 of the Articles of Association so that the limits for the share capital and the number of shares in the company are changed. The...

Read more

Biovica Secures Major Work Order for TKa Testing Services

January 13, 2025 2:20 AM

UPPSALA, SE / ACCESSWIRE / January 13, 2025 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, has signed an order with a total value of 2.3 MSEK for TKa testing services within its Pharma Services business. The work order is signed with a UK-based pharma/biotech company to be used in a phase I/II clinical study in patients with advanced solid tumors being treated with a next...

Read more

Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week

January 10, 2025 8:30 AM

LAS VEGAS, NV / ACCESSWIRE / January 10, 2025 / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025, in San Francisco, California. Alyea is developing innovative, actionable solutions intended to help end the opioid crisis with its lead...

Read more

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

January 10, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations. Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and...

Read more

Lumira Ventures Announces Promotion of Suman Rao to Principal

January 10, 2025 7:00 AM

TORONTO, ON / ACCESSWIRE / January 10, 2025 / Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions....

Read more

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

January 10, 2025 6:30 AM

LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has achieved ISO 26000 verification, an internationally recognized standard. This achievement highlights BioInvent's dedication to...

Read more

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

January 9, 2025 3:00 PM

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body...

Read more

The FDA Continues to Intimidate Doctors and Defraud the American Public

January 9, 2025 10:00 AM

The Golden Gift announced today that affordable plasma interventions can have significant health and economic benefits to prevent or manage age-related conditions that account for a majority of our nation's $4.5 trillion in annual health care expenditures: https://www.youngplasmastudy.com. Plasma was approved for medical use by the Federal Food, Drug, and Cosmetic Act of 1938 (FDCA) and since the formation of the Junior Red Cross on November 1,...

Read more

Genvara Biopharma to Present at Biotech Showcase 2025 and Lytham Partners 2025 Investor Healthcare Summit

January 8, 2025 12:40 PM

Genvara Biopharma, Inc., a biopharmaceutical company developing pharmacogenetically-targeted therapies for cardiovascular diseases acting through novel mechanisms of action, today announced that Thomas Keuer, Chief Executive Officer, will present at the Biotech Showcase 2025, taking place January 13-15, 2025 in San Francisco, California and Genvara will also participate in a webcasted company presentation at the Lytham Partners 2025 Investor...

Read more